Alliance Global Partners analyst James Molloy upgraded Alimera Sciences to Buy from Neutral with a price target of $8, up from $4.50, after the company bought the U.S. commercial rights of Yutiq. The analyst sees it as a “significant positive” that Alimera has added a complementary product, and says Yutiq does adds an immediate $30M-$40M to its annual sales. Yutiq brings in an additional uveitis indication to Alimera’s pipeline, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALIM:
- Alimera Soars as it Snaps Up Rights for Yutiq from EyePoint Pharma
- Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET
- Alimera Sciences Reports First Quarter 2023 Results
- Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update